Objective. To assess an efficacy of prostaglandin E1 (PGE1) in complex therapy of inoperable critical lower limb ischemia within one-year follow up period using WIfI classification system. Material and methods. A retrospective, multiple-center trial included 109 patients (60 men and 49 women). Mean age was 70±7,3 years. Patients were divided into 2 groups. Group 1 (n=58) — standard therapy without PGE1, group 2 (n=51) — standard therapy with PGE1. Statistical analysis included chi-square test with Fisher’s exact test, log-rank test. Results. There were no significant between-group differences in all endpoints within one-year follow up period. Conclusion. PGE1 in complex conservative treatment does not influence major amputation rate, amputation-free survival and overall mortality in patients with critical lower limb ischemia for all WIfI combinations (130, 131, 230, 231) within one-year follow up period. © 2020, Media Sphera Publishing Group. All rights reserved.